The landscape of dermatology research and treatment has changed rapidly in recent years, and the pipeline is highly active, with over 900 products in development.

Unlike the market, which is almost entirely dominated by small molecules, the dermatology pipeline contains a high number of biologics, many of which are monoclonal antibodies (mAbs) that specifically target proinflammatory cytokines and cytokine receptors – a target class that is under-represented in the marketed product landscape.

The strong presence of these products in the late-stage pipeline is likely to have a considerable impact on dermatology treatment.

Broadened horizons

These innovative therapies have only been used for a little over a decade in dermatology, and have mainly been restricted to use in psoriasis.

However, there is now a rising commercial interest in the use of mAbs in the broader dermatology field – particularly for indications with a strong inflammatory component.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These conditions have traditionally relied on steroidal and systemic treatments, which have been associated with side-effects following long-term use.

Early success

Atopic dermatitis has been the first condition to benefit, with the mAb Dupixent (dupilumab), receiving FDA approval in March for moderate-to-severe disease.

The drug was also granted early access to eligible patients with severe atopic dermatitis in the UK.

Previous products approved under this scheme have mainly been for life-limiting conditions, which indicate the pressing need for access to such therapies for sufferers of dermatological conditions.

Pipeline of possibilities

There are other mAbs in development for atopic dermatitis, as well as for other conditions including alopecia, acne vulgaris and bullous pemphigoid.

Furthermore, a considerable proportion of pipeline products are first in class, with many being developed for indications for which there is a significant need for safe and effective therapeutic options, such as scleroderma and cutaneous lupus erythematosus.

The high number of new non-steroidal topical and systemic pipeline products is incredibly promising, and highlights the renewed interest in the previously stagnant and highly genericized dermatology market.